CA3036111C - Colloidal particles for use in medicine - Google Patents

Colloidal particles for use in medicine Download PDF

Info

Publication number
CA3036111C
CA3036111C CA3036111A CA3036111A CA3036111C CA 3036111 C CA3036111 C CA 3036111C CA 3036111 A CA3036111 A CA 3036111A CA 3036111 A CA3036111 A CA 3036111A CA 3036111 C CA3036111 C CA 3036111C
Authority
CA
Canada
Prior art keywords
composition
amphipathic lipid
formulated
colloidal particle
haemophilia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3036111A
Other languages
English (en)
French (fr)
Other versions
CA3036111A1 (en
Inventor
William Henry
Richard WOLF-GARRAWAY
John Mayo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cantab Biopharmaceuticals Patents Ltd
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of CA3036111A1 publication Critical patent/CA3036111A1/en
Application granted granted Critical
Publication of CA3036111C publication Critical patent/CA3036111C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3036111A 2015-10-14 2016-10-14 Colloidal particles for use in medicine Active CA3036111C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1518172.0 2015-10-14
GBGB1518172.0A GB201518172D0 (en) 2015-10-14 2015-10-14 Colloidal particles for use in medicine
PCT/EP2016/074759 WO2017064276A1 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine

Publications (2)

Publication Number Publication Date
CA3036111A1 CA3036111A1 (en) 2017-04-20
CA3036111C true CA3036111C (en) 2023-06-06

Family

ID=55131025

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3036111A Active CA3036111C (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine

Country Status (15)

Country Link
US (3) US20190192664A1 (https=)
EP (1) EP3362039A1 (https=)
JP (1) JP7160678B2 (https=)
KR (1) KR20180067616A (https=)
CN (1) CN108472246A (https=)
AU (1) AU2016336929B2 (https=)
BR (1) BR112018007399A2 (https=)
CA (1) CA3036111C (https=)
EA (1) EA201890703A1 (https=)
GB (1) GB201518172D0 (https=)
HK (1) HK1256814A1 (https=)
IL (1) IL258567B2 (https=)
MX (1) MX391574B (https=)
SG (2) SG10202010711UA (https=)
WO (1) WO2017064276A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021092580A1 (en) * 2019-11-07 2021-05-14 The Board Of Trustees Of The University Of Illinois Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111758D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111759D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0815852A1 (en) 1993-08-06 1998-01-07 Opperbas Holding B.V. A method for high loading of vesicles with biopolymeric substances
US6593294B1 (en) 1998-04-27 2003-07-15 Opperbas Holding B.V. Pharmaceutical composition comprising Factor VIII and neutral liposomes
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DK1198490T3 (da) 1999-07-14 2006-06-19 Alza Corp Neutral lipopolymer og liposomsammensætninger indeholdende samme
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
CN1774281B (zh) * 2003-04-15 2010-10-13 奥珀百思控股公司 包含蛋白质和/或多肽以及胶体颗粒的药物组合物
CA2613705A1 (en) * 2005-06-29 2007-01-04 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic pr0tein-lip1d complexes
CN105434353A (zh) 2009-06-03 2016-03-30 斯昆申技术控股有限责任公司 用于治疗深部组织疼痛的制剂
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
CN107879960B (zh) * 2013-03-08 2021-06-22 诺华股份有限公司 用于传递活性成分的脂质和脂质组合物

Also Published As

Publication number Publication date
US20210093721A1 (en) 2021-04-01
SG10202010711UA (en) 2020-12-30
GB201518172D0 (en) 2015-11-25
WO2017064276A1 (en) 2017-04-20
US20250170244A1 (en) 2025-05-29
IL258567A (en) 2018-05-31
EP3362039A1 (en) 2018-08-22
AU2016336929B2 (en) 2022-09-29
EA201890703A1 (ru) 2018-11-30
IL258567B2 (en) 2025-08-01
AU2016336929A1 (en) 2018-05-10
JP7160678B2 (ja) 2022-10-25
BR112018007399A2 (pt) 2018-10-16
IL258567B1 (en) 2025-04-01
MX391574B (es) 2025-03-21
SG11201802956RA (en) 2018-05-30
JP2018535952A (ja) 2018-12-06
CA3036111A1 (en) 2017-04-20
MX2018004445A (es) 2018-08-14
KR20180067616A (ko) 2018-06-20
HK1256814A1 (zh) 2019-10-04
US20190192664A1 (en) 2019-06-27
CN108472246A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
US20250170244A1 (en) Colloidal particles for use in medicine
RU2572213C2 (ru) Офтальмологическая система доставки лекарственного препарата, содержащая фосфолипид и холестерин
KR20240040125A (ko) A형 혈우병 치료용 변형된 콜로이드 입자
JP7573582B2 (ja) Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
WO2017064289A1 (en) Colloidal particles for topical administration with therapeutic agent
WO2017064300A1 (en) Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
US20240358801A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
US20250064738A1 (en) Modified colloidal particles for use in the treatment of haemophilia a

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211008

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250326

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250326

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260105